Zydus to settle Mirabegron patent litigation with Astellas by paying $120 million
Zydus agrees to pay Astellas $120 million, settling patent litigation and allowing continued sales of generic Mirabegron in the U.S.
Zydus agrees to pay Astellas $120 million, settling patent litigation and allowing continued sales of generic Mirabegron in the U.S.